General Partner


Business Programme Partner

Business Breakfast Partner

Organization Partner

Joint Stock Company “Russian Railways”

Joint Stock Company “Russian Railways” is one of the largest rail companies in the world with huge volumes of passenger and freight transportation.

The company has high financial ratings, qualified specialists in all the rail business spheres, extensive scientific and technological basis, project and construction facilities, experience in international cooperation.

100% of the stock of the company operating the railways network as long as 85,5 thousand kilometers belongs to the Russian Federation.

Every year Russian Railways carries more than 1 billion passengers and ships up to 45% of the country's cargo turnover (including pipelines).

Russian Railways belongs to the top 3 of the world rail industry leaders.

The company’s mission is to meet the market demand for transportation services, increase efficiency, quality of services and deep integration into the Eurasian transport system.

For more than 125 years, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. MSD has been operating in Russia since 1991 with a focus on delivering innovative medicines and vaccines, cooperation with local manufacturers and leading medical institutions, clinical research programs, as well as medical education and information support. We use our global expertise to contribute to the development of healthcare and pharmaceutical industry in Russia.

About Philips

Philips is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2017 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at

Pharmasyntez Group of Companies is the largest manufacturer in Russia dealing in development and production of modern, high-quality, affordable medicines.

Pharmasyntez is one of the three fastest growing Russian pharmaceutical companies; is in the TOP-10 Russian pharmaceutical companies in terms of drugs production and in the TOP-10 Leading manufacturers in terms of hospital purchases, and also ranks second in the manufacturers' rating in the segment of prevention and treatment facilities.

Pharmasyntez Company is the largest domestic manufacturer of socially significant medicines in Russia nowadays, with an annual turnover of about 20 billion rubles. The company owns five plants in the cities of Saint Petersburg, Tyumen, Irkutsk, Bratsk, and Ussuriysk. The company’s product pipeline numbers 160 pharmaceutical drugs.

The company successfully invests its own projects; the total investment between 2018 and 2021 will come to over 20 billion rubles.

The volume of investments in production in the period 2018-2021 will exceed 20 billion rubles:

- Pharmasyntez-Nord JSC, St. Petersburg - antitumor drugs.

- Pharmasyntez-Tyumen LLC, Tyumen - hormonal and radiopaque drugs.

- BratskKhimSyntez LLC, Bratsk - active pharmaceutical substances

«Рош» (Базель, Швейцария) — глобальная инновационная компания в области фармацевтики и диагностики, которая использует передовую науку, чтобы улучшить жизни людей. В 2018 году инвестиции компании в исследования и разработки составили 11 млрд швейцарских франков. «Рош» является одним из крупнейших разработчиков и производителей биотехнологических лекарственных препаратов для лечения онкологических, аутоиммунных, инфекционных и неврологических заболеваний. Компания также является одним из лидеров в области диагностики in vitro и гистологической диагностики онкологических заболеваний, а также пионером в области самоконтроля сахарного диабета. Объединение фармацевтического и диагностического подразделений позволяет «Рош» быть одним из лидеров в области персонализированной медицины. АО «Рош-Москва» представляет в России фармацевтическое подразделение компании. Работая со всеми заинтересованными сторонами, мы стремимся улучшить доступ российских пациентов к инновационным технологиям в лечении заболеваний. 27 препаратов компании входят в перечень ЖНВЛП. «Рош» вносит долгосрочный вклад в развитие медицины, науки, общественного здравоохранения и фармацевтической промышленности в России. Подробнее на

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda Pharmaceuticals, LLC located in Moscow, is the Russian marketing and sales organization of Takeda Pharmaceutical Company Limited, Osaka, Japan. 

Improving the health and quality of life is the main goal of the pharmaceutical company Beringer Ingelheim. The company concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. The company has been successfully operating in the Russian market for more than 25 years. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals.

Sberbank is Russia’s largest bank and a leading global financial institution. Sberbank holds almost one third of aggregate Russian banking sector assets, it is the key lender to the national economy and the biggest deposit taker in Russia. The Central Bank of the Russian Federation is the founder and principal shareholder of Sberbank owning 50% of the bank’s authorised capital plus one voting share, with the remaining 50% held by domestic and international investors. Sberbank has customers in 18 countries. Sberbank has the largest distribution network in Russia with about 14,000 branches, and its international operations include the UK, US, CIS, Central and Eastern Europe, India, China, and other countries.

The bank holds general banking licence No. 1481 issued by the Bank of Russia. 

For 130 years Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, minimally invasive medical devices, coronary stents, nutritionals and branded generic medicines. We help people with diabetes effectively manage it without painful finger pricks.

Abbott is one of the most diversified companies in healthcare. Our 107,000 colleagues serve people in more than 160 countries.


Abbott was one of the first foreign investors by opening baby nutrition manufacturing 40 years ago in the USSR. In 2014 Abbott acquired Veropharm, since then strategically executing manufacturing modernization, technology transfer and localization of medicines. Abbott’s manufacturing sites located in Volginsky of Vladimir region, Belgorod and Voronezh. In Russia Abbott employs over 3500 people.


Our company is a strategic investor and supports modern healthcare development. We strive to make quality medicines and innovative medical technologies more accessible to more people in Russia.

Learn more:;

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries.

A high-tech manufacturing facility for modern insulin production located has opened in Kaluga in 2015. In 2018 the full-cycle production with original substance produced in Denmark has been launched.

GSK is an international pharmaceutical research company that develops and manufactures innovative medicines, vaccines, and healthcare products. Millions of people around the world use our products to help them do more, feel better, and live longer.

More than 100 GSK prescription drugs have been registered in Russia. GSK prescription drugs are used to treat diseases of the respiratory organs, infectious diseases, including HIV, diseases of the central nervous system, and also for urology, immunology, dermatology, and vaccination. GSK is one of the industry leaders in terms of investment in research in Russia.

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world.

Company has more than 120 years of history in Russia. From the opening of the first pharmaceutical factory in the late 19th century up to the present day Novartis Group has always been a reliable partner for Russia in the development of health care and improvement of the patient access to quality health care services. All Company's business units and production facility are currently presented in Russia, more than 2,000 Novartis employees are working for the benefit of patients in the majority of the Russian regions.

 Established in 1995, JSC Multon is a Russian innovative company developing, producing and distributing functional food made of fruit: natural juices, nectars and juice containing drinks. Since 2005 Multon has joined Coca-Cola in Russia representing its juice business. The company owns the Russian № 1 juice brand* Dobry, which is suitable for daily consumption, according to the research conducted in 2019 in Moscow "Assessment of the tolerance of fruit and vegetable juices  "Multon", produced under the “Dobry” trademark, in the daily diet of children of preschool and school age " from 20.06.2019.

Coca-Cola in Russia operates one of the biggest plants in Europe—Schyolkovo (Moscow Region). Multon also owns an innovative R&D Centre.

* Dobry brand is the #1 brand in the juice sales category (volume/value) in Russia from Jan '19 to Nov'19 based on Nielsen RI research.

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2018, Merck generated sales of € 14.8 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

DNA health - is a magazine about medicine – the printing edition that calls readers to watch over their health condition in order to avoid risk of development of various diseases probability in the future and by that to ensure long and full-fledged life.

Each magazine informs on relevant topics in the field of medicine, food, beauty, sport, rest and other important aspects of quality of life.

International media project, GMP News, has existed since 2010 and is a multilingual network that includes news, events, websites, and magazines. General task - Present Russia and EEU and CIS countries' pharmaceutical markets to the global markets.

Over the years, the publication has been published, not only in a regular Russian-language version, but also in English, Arabic, Spanish, Chinese and German. In addition to the industry editions, "GMP News" and "CIS GMP News", the editors publish specialized thematic issues. Regarding the actual news, we are publishing it in two languages on both and It is distributed at the largest industry events in Russia, as well as on the world markets.

"Parlamentskaya gazeta" is the official weekly edition of the Federal Assembly of the Russian Federation. Published since 1997. The founders of the newspaper - the State Duma and the Federation Council. The publication is the official publisher of Federal laws, regulations, acts and other documents of the Federal Assembly. "Parlamentskaya gazeta"  has press points and representations in ten reagions. The website of the "Parlamentskaya gazeta"  PNP.RU is operational news and reliable information about the laws adopted in the country and the activities of deputies and senators.

Russian Physician Publishing House publishes the following scientific magazines:

Physician – for physicians of all professions;

Nurse – for nurses;

Pharmacy – for chemists, pharmacists, manufacturers, and production engineers.

Molecular Medicine publishes the results of scientific studies on the molecular and genetic makeup of the etiology and pathogenesis of human diseases.

Sports Medicine: Science and Practice – information for sports doctors.

Biological, Medical, and Pharmaceutical Chemistry Issues.

All the magazines are included in the list of the State Commission for Academic Degrees and Titles. (Doctors United) is an educational social network for doctors. The web portal editors have prepared over 2,500 exclusive educational videos for different medical specialists. The video archive includes recorded conference reports on vital topics, video lectures by Russian and foreign PhDs in medicine, documentaries and interviews on relevant medical issues. Our web portal regularly holds webinars which provide you with a unique opportunity to ask questions online. encourages knowledge exchange, professional communication, and forming new contacts. Feel free to join us! is the specialized portal for doctors and health officials. includes a news feed, a library of professional publications, the Encyclomedia medical knowledge base and the Medvestnik TV video channel.

The Doctor TV channel is the first popular science and educational channel about medicine. We offer mainstream audiences a programme about medical science achievements as well as new methods for the diagnosis and treatment of diseases.

The Doctor channel presents:

–        Leading experts from Russia and around the world

–        Fundamental science and new ideas in the medicine industry

–        Innovative methods for the diagnosis and treatment of diseases

–        Modern technologies and medical equipment.

Health is a subject that concerns everyone!

Pharmvestnik (‘Pharmaceutical Herald’) is the leading specialized media covering the Russian pharmaceutical industry.

Pharmvestnik carries opinions of market leaders, leading experts, authorities and public organizations.

It covers the various sectors of the Russian pharma market and provides regulatory analysis as well as offers practical advice valuable in the pharmacist’s and HR manager’s perspective. Equal coverage is also given to all Russia’s federal districts as Pharmvestnik has regional representatives in all major cities and towns.

The professional medical magazine Poliklinika has been published since 1999. It is designed for managers and physicians working in all professions at healthcare facilities. In our magazine, you will find: information about legislative and regulatory documents in healthcare and the activities of the Russian Ministry of Health; science and practical medicine news; expert advice for healthcare facility employees; articles about new drugs and methods for their use, and medical equipment.

Poliklinika magazine is included in the Russian Science Citation Index (RISC) system and has been assigned the International Standard Serial Number ISSN 2311-2441 as its unique identifier.

The magazine is published in A4 format and has circulation of 14,000 copies.

Distribution form:

• subscription through the Rospechat agency’s catalogue;

• subscription through the editoral board;

• direct mailing to healthcare facilities;

• distribution at exhibitions.


“Healthcare of Russia” is the annual journal of the publishing house EuroMedia.

The most voluminous magazine for specialists in the field of medicine and pharmaceuticals in Russia. Published since 2012. Magazine for medical and pharmaceutical workers, as well as for distribution in the venues of medical and pharmaceutical exhibitions, seminars, conferences and other similar events.

In 2016, the magazine entered the Book of Records of Russia as the most voluminous publication for specialists in the field of medicine and pharmaceuticals in the Russian Federation. The magazine has repeatedly received high marks from leading specialists in the Russian medical industry.

Each journal “Healthcare of Russia” is designed for a long period and will allow you to get the most complete picture of the potential and prospects for the development of the health care system of the regions of the Russian Federation.

“Remedium” Group of Companies renders the whole range of services for specialists in the field of medicine and pharmaceutics. For years the principle directions of activity of “Remedium”, “Rossiiskie apteki”, “Meditsinskiy Sovet”, “Ambulatory surgery”, “Aterotromboz” Group of Companies are publication of particularized periodicals, assignment of electronic databases, arrangement and implementation of measures, rent-a-rep service, organization of advertisement and PR support.

The journal provides a multi-faceted dialogue on the implementation of health care programs, the development of modern medical technologies, improving organizational activities, finding effective innovative solutions, serves as a tool in personnel policy, strengthening the reputation and stimulating the best employees, ensuring the progress and professional success of domestic medicine. The journal has been published since 2003 in 6 open access formats. Choose a convenient format and join the dialogue

Exhibitors 2020

Central Health Directorate – branch of JSC ‘Russian Railway’ administers Russias’ largest healthcare network under the RZD-Medicine brand spread well across 75 regions. RZD-Medicine provides medical services for 2.5 mln. of Russian populations. There are 32 mln. visits annually. Network employs almost 60 thousands of medical specialists and staff workers. With its 175-year history, RZD-Medicine combines experience and modern practices while providing medical services, including high-tech in each of 220 medical organizations consisting network. The largest clinics has its own oncological and cardiovascular centers as well as some other high-efficient directions. Network is the well-known leader in professional medicine. About 1.6 mln. mandatory medical examinations are carried out per year as well as 29 mln. regular medical examinations of railway workers.

MyGenetics is a high-tech company that develops and conducts DNA research in such areas as food, sports, cosmetology, neurogenetics, and health. The company has been in operation since 2013 and is among the leaders in the direct to consumer segment (working directly with clients) on the DNA test market. It develops technologies in collaboration with leading research institutes of the Siberian Branch of the Russian Academy of Sciences and advanced genetics and bioinformatics research groups. We study genes and interpret their results in order to provide people with a tool to improve their quality of life, maintain their health and youth, enhance their productivity, and efficiently use the resources of their bodies.